Freehold Royalties Ltd. Declares Dividend for January 2021

Written by Customer Service on January 14, 2021. Posted in Dividend Reports And Estimates.

CALGARY, Alberta, Jan. 14, 2021 (GLOBE NEWSWIRE) — Freehold Royalties Ltd. (Freehold) (TSX:FRU) announces that its Board of Directors has declared a dividend of Cdn. $0.02 per common share to be paid on February 16, 2021 to shareholders of record on January 31, 2021.These dividends are designated as “eligible dividends” for Canadian income tax purposes.Freehold’s focus is on acquiring and managing oil and gas royalties. Freehold’s common shares trade on the Toronto Stock Exchange in Canada under the symbol FRU.For further information, contact:Freehold Royalties Ltd.Matt DonohueManager, Investor Relations & Capital Marketst. 403.221.0833f. 403.221.0888tf. 1.888.257.1873e. mdonohue@rife.comw. www.freeholdroyalties.com

CarGurus Completes Acquisition of CarOffer

Written by Customer Service on January 14, 2021. Posted in Mergers And Acquisitions.

CAMBRIDGE, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) — CarGurus (Nasdaq: CARG), a leading global online automotive marketplace, today announced it has completed the acquisition of a 51% interest in CarOffer, with the ability to buy the remaining equity interest in the company over the next three years. The acquisition adds wholesale vehicle acquisition and selling capabilities to CarGurus’ portfolio of dealer offerings. CarOffer was founded by auto industry veteran, Bruce Thompson, who will continue to lead the CarOffer brand and team from their Plano, Texas location.“We are thrilled to welcome the CarOffer team to the CarGurus family and excited to join forces to drive further innovation and value for our customers,” said Jason Trevisan, Chief Financial Officer at CarGurus. “Digital wholesale creates exciting new opportunities for...

Accolade to Acquire 2nd.MD

Written by Customer Service on January 14, 2021. Posted in Public Companies.

The addition of 2nd.MD’s Expert Medical Opinion services to Accolade’s portfolio of high-touch, technology-enabled health and benefits solutions expands Accolade’s clinical capabilities and creates the market’s most comprehensive, integrated healthcare navigation experience.SEATTLE, Jan. 14, 2021 (GLOBE NEWSWIRE) — Accolade, Inc. (Nasdaq: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate and utilize the healthcare system and their workplace benefits, today announced it has signed a definitive agreement to acquire Innovation Specialists, LLC (d/b/a 2nd.MD), a leading Expert Medical Opinion and medical decision support company based in Houston, TX. With healthcare utilization expected to rise significantly in 2021, on the heels of the COVID-19 pandemic, the integration of...

ShiftPixy, Inc. Reports Fiscal 2021 Q1 Results

Written by Customer Service on January 14, 2021. Posted in Earnings Releases And Operating Results.

MIAMI, Jan. 14, 2021 (GLOBE NEWSWIRE) — ShiftPixy, Inc. (NASDAQ: PIXY), a Florida-based staffing enterprise that designs, manages, and sells access to a disruptive, revolutionary platform that facilitates employment in the rapidly growing Gig Economy, today announced results for the quarter ended November 30, 2020 (“2021 First Quarter”).2021 First Quarter Financial HighlightsImproved balance sheet with cash position of $9.1 million and no long-term debt as of November 30, 2020, compared to cash of $4.3 million and no long-term debt as of August 31, 2020.Successfully closed public equity offering yielding gross proceeds of $12 million on October 14, 2020.Net Loss excluding non-recurring items was $6.9 million, or $0.22 per share.Operating Loss of $5.6 million for the 2021 First Quarter as compared to $4.2 million for the same period...

Wesdome Announces 2020 Fourth Quarter and Full Year Production Results; Provides 2021 Guidance

Written by Customer Service on January 14, 2021. Posted in Earnings Releases And Operating Results.

TORONTO, Jan. 14, 2021 (GLOBE NEWSWIRE) — Wesdome Gold Mines Ltd. (TSX: WDO) (“Wesdome” or the “Company”) today announces fourth quarter (“Q4”) and full year 2020 production results and 2021 guidance. All figures are in Canadian dollars unless otherwise stated.Production from the Eagle River Complex in Q4 2020 totaled 20,006 ounces of gold, putting full year 2020 production at 90,278 ounces, meeting the low end of our unadjusted 2020 production guidance.2020 Highlights:Eagle River gold production of 196,441 tonnes at a head grade of 14.2 grams per tonne and a recovery rate of 97.7% producing 87,560 ounces, 1% lower than 2019Mishi gold production of 39,856 tonnes at a head grade of 2.7 grams per tonne and a recovery rate of 77.8%, producing 2,718 ounces of gold, Mishi mining operations finished in Q4. The Mishi stockpile now contains...

Kaiser Aluminum Corporation Announces a 7.5 Percent Increase in Quarterly Dividend Payment

Written by Customer Service on January 14, 2021. Posted in Dividend Reports And Estimates.

FOOTHILL RANCH, Calif., Jan. 14, 2021 (GLOBE NEWSWIRE) — Kaiser Aluminum Corporation (NASDAQ:KALU) today announced that its Board of Directors has declared a quarterly cash dividend of $0.72 per share representing a 7.5% increase over the prior quarter’s dividend. The dividend will be payable on February 12, 2021 to shareholders of record as of the close of business on January 25, 2021.“The increase in the quarterly dividend reflects our continued confidence in the long-term outlook for our business, the end markets we serve and opportunities to create value for our shareholders,” said Keith A. Harvey, President and CEO. “In addition, our planned acquisition of the Warrick Rolling Mill from Alcoa, provides excellent potential for further value creation with strong secular demand growth and due to the non-cyclic nature of the...

ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

Written by Customer Service on January 14, 2021. Posted in Public Companies.

ERYTECH Announces First Patient Enrolled ina Phase 1 Investigator Sponsored Trial ofEryaspase in First-Line Pancreatic CancerTrial to evaluate safety of eryaspase in combination with FOLFIRINOX for the first-line treatment of pancreatic cancerTrial in Progress (TiP) poster accepted for presentation at the American Society of Clinical Onocology – Gastrointestinal Cancers Symposium (ASCO GI)Lyon (France) and Cambridge, MA (U.S.), January 14th, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the first patient enrolled in a Phase 1 investigator sponsored trial (IST), named rESPECT, of its lead product eryaspase for the first-line treatment of pancreatic cancer.The rESPECT Phase...

ERYTECH annonce le recrutement du premier patient dans une étude de phase 1 conduite par un investigateur avec eryaspase dans le traitement de première ligne du cancer du pancréas

Written by Customer Service on January 14, 2021. Posted in Public Companies.

ERYTECH annonce le recrutement du premier patient dans une étude de phase 1 conduite par un investigateur avec eryaspase dans le traitement de première ligne du cancer du pancréas Etude pour évaluer la sécurité d’eryaspase en combinaison avec FOLFIRINOX dans le traitement de première ligne du cancer du pancréasSélection du poster de l’étude en cours pour une présentation lors du symposium de l’American Society of Clinical Oncology (ASCO) 2021 sur les cancers gastro-intestinauxLyon (France), le 14 janvier 2021 – ERYTECH Pharma (Euronext Paris et Nasdaq : ERYP), société biopharmaceutique de stade clinique qui développe des thérapies innovantes en encapsulant des médicaments dans les globules rouges, annonce aujourd’hui le recrutement du premier patient dans une étude clinique de phase 1, nommée rESPECT, conduite par un investigateur...

DBV Technologies Provides Update on Investigational Viaskin™ Peanut for Children Ages 4-11 Years

Written by Customer Service on January 14, 2021. Posted in Public Companies.

Montrouge, France, January 14, 2020DBV Technologies Provides Update on Investigational Viaskin™ Peanut for Children Ages 4-11 YearsDBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the receipt of written responses from the U.S Food and Drug Administration (FDA) to questions provided in the Type A meeting request the Company submitted in October 2020. The Type A meeting request was submitted following the Company’s receipt of a Complete Response Letter (CRL) in connection with its Biologics License Application (BLA) for Viaskin™ Peanut (DBV712), an investigational, non-invasive, once-daily epicutaneous patch to treat peanut allergy in children ages 4 to 11 years.DBV believes that the feedback received from the FDA provides a well-defined regulatory...

DBV Technologies annonce des avancées règlementaires sur ViaskinTM Peanut pour les enfants âgés de 4 à 11 ans

Written by Customer Service on January 14, 2021. Posted in Public Companies.

Montrouge, France, le 14 janvier (22 h 30 CET), 2021DBV Technologies annonce des avancées règlementaires sur ViaskinTM Peanut pour les enfants âgés de 4 à 11 ansDBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT), une société biopharmaceutique au stade clinique, a annoncé aujourd’hui la réception de réponses écrites de la part de la Food and Drug Administration (FDA) américaine aux questions figurant dans la demande de réunion de type A que la société a présenté en octobre 2020. La demande de réunion de type A a été formulée suite à la réception par la société d’une Lettre de Réponse Complète (CRL) en lien avec sa demande de licence de produits biologiques (BLA) pour Viaskin™ Peanut (DBV712), un patch épicutané expérimental, non invasif, à prise quotidienne unique, visant à traiter l’allergie aux arachides...

Day: January 14, 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice